Literature DB >> 505339

Structural alterations to the pulmonary circulation in fulminant hepatic failure.

A Williams, P Trewby, R Williams, L Reid.   

Abstract

Like patients with chronic liver disease, those with coma due to fulminant hepatic failure may show arterial hypoxaemia even in the absence of pulmonary complications, and in both it is attributed to increased intrapulmonary arteriovenous admixture. This study is concerned with the structural alterations in the pulmonary circulation of patients who have died from fulminant hepatic failure. Precise quantitative morphometric techniques applied to the injected and inflated lung have shown the major abnormality to be a diffuse dilatation of the pulmonary vascular bed affecting arteries and veins of all structural types. At an intra-acinar level the diameter of arteries accompanying respiratory bronchioles was 232.97 micron (+/-SD 46.35) compared with 177.76 micron (+/-SD 30.43) in controls (P less than 0.01). In two-thirds of the patients pleural spider naevi were seen and, throughout the lung, similar significant dilatation of precapillary vessels; but in only one patient were precapillary anastomoses shown. While intrapulmonary venous admixture undoubtedly contributes to hypoxia in fulminant hepatic failure, its exact relation to the structural changes is not yet determined.

Entities:  

Mesh:

Year:  1979        PMID: 505339      PMCID: PMC471095          DOI: 10.1136/thx.34.4.447

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  16 in total

1.  Biochemical, blood gas and peripheral circulatory alterations in hepatic coma.

Authors:  M P TYOR; H O SIEKER
Journal:  Am J Med       Date:  1959-07       Impact factor: 4.965

2.  Multiple pulmonary arteriovenous fistulas in juvenile cirrhosis.

Authors:  F W HOFFBAUER; R RYDELL
Journal:  Am J Med       Date:  1956-09       Impact factor: 4.965

3.  Hypoxemia of cirrhosis: detection of abnormal small pulmonary vascular channels by a quantitative radionuclide method.

Authors:  J D Wolfe; D P Tashkin; F E Holly; M B Brachman; M G Genovesi
Journal:  Am J Med       Date:  1977-11       Impact factor: 4.965

Review 4.  Acute liver failure. Experience in a special unit.

Authors:  M E Ward; P N Trewby; R Williams; L Strunin
Journal:  Anaesthesia       Date:  1977-03       Impact factor: 6.955

5.  Hepatic damage and death from overdose of paracetamol.

Authors:  R Clark; V Borirakchanyavat; A R Davidson; R P Thompson; B Widdop; R Goulding; R Williams
Journal:  Lancet       Date:  1973-01-13       Impact factor: 79.321

6.  Impairment of lung function after portacaval anastomosis.

Authors:  J E Cotes; G B Field; G J Brown; A E Read
Journal:  Lancet       Date:  1968-05-04       Impact factor: 79.321

7.  Fetal and childhood development of the intrapulmonary veins in man--branching pattern and structure.

Authors:  A Hislop; L Reid
Journal:  Thorax       Date:  1973-05       Impact factor: 9.139

8.  Failure of hypoxic pulmonary vasoconstriction in patients with liver cirrhosis.

Authors:  F S Daoud; J T Reeves; J W Schaefer
Journal:  J Clin Invest       Date:  1972-05       Impact factor: 14.808

9.  The circulation, the lung, and finger clubbing in hepatic cirrhosis.

Authors:  N N Stanley; D J Woodgate
Journal:  Br Heart J       Date:  1971-07

10.  Pulmonary function studies and oxygen transfer in patients with liver cirrhosis and different degree of portasystemic encephalopathy.

Authors:  H Schomerus; I Buchta; H Arndt
Journal:  Respiration       Date:  1975       Impact factor: 3.580

View more
  16 in total

1.  Pathogenesis of pulmonary arteriovenous malformations: role of hepatopulmonary interactions.

Authors:  J J Vettukattil
Journal:  Heart       Date:  2002-12       Impact factor: 5.994

2.  The hepatopulmonary syndrome: new name, old complexities.

Authors:  R Rodríguez-Roisin; A G Agustí; J Roca
Journal:  Thorax       Date:  1992-11       Impact factor: 9.139

Review 3.  Vasodilatation associated with hepatocellular disease: relation to functional organ failure.

Authors:  S Sherlock
Journal:  Gut       Date:  1990-04       Impact factor: 23.059

4.  [Hepatopulmonary syndrome].

Authors:  G P Glattki; C Maurer; N Satake; R Lange; K Metz; M Wettstein; U Costabel
Journal:  Med Klin (Munich)       Date:  1999-09-15

5.  Arterial hypoxemia and intrapulmonary vasodilatation in rat models of portal hypertension.

Authors:  Yasumi Katsuta; Xue-Jun Zhang; Masaru Ohsuga; Toshio Akimoto; Hirokazu Komeichi; Shuji Shimizu; Yoshihito Kato; Akiko Miyamoto; Katsuaki Satomura; Teruo Takano
Journal:  J Gastroenterol       Date:  2005-08       Impact factor: 7.527

6.  Non-cirrhotic portal hypertension with hypoxaemia.

Authors:  C Babbs; T W Warnes; N Y Haboubi
Journal:  Gut       Date:  1988-01       Impact factor: 23.059

7.  Sorafenib in Hepatopulmonary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Steven M Kawut; Susan S Ellenberg; Michael J Krowka; David Goldberg; Hugo Vargas; David Koch; Tiffany Sharkoski; Nadine Al-Naamani; Alyson Fox; Robert Brown; Joshua Levitsky; Jae K Oh; Grace Lin; Nianfu Song; Carl Mottram; Margaret F Doyle; David E Kaplan; Samir Gupta; Michael B Fallon
Journal:  Liver Transpl       Date:  2019-05-30       Impact factor: 5.799

Review 8.  The altered pharmacokinetics and pharmacodynamics of drugs commonly used in critically ill patients.

Authors:  A Bodenham; M P Shelly; G R Park
Journal:  Clin Pharmacokinet       Date:  1988-06       Impact factor: 6.447

9.  The relationship between severity of liver cirrhosis and pulmonary function tests.

Authors:  Irem Pembegul Yigit; Suleyman Savas Hacievliyagil; Yuksel Seckin; Ramazan Ilyas Oner; Melih Karincaoglu
Journal:  Dig Dis Sci       Date:  2007-12-13       Impact factor: 3.199

Review 10.  Synapomorphic features of hepatic and pulmonary vasculatures include comparable purinergic signaling responses in host defense and modulation of inflammation.

Authors:  Dusan Hanidziar; Simon C Robson
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2021-06-09       Impact factor: 4.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.